Recent News
Click here to join our mailing list for the latest news and updates
July 27, 2010
MABCURE ANNOUNCES POSITIVE RESULTS FOR NEW OVARIAN CANCER DIAGNOSTIC BLOOD TEST
» MORE
June 1, 2010
MEMORANDUM TO SHAREHOLDERS FROM DR. AMNON GONENNE, MABCURE’S CHIEF EXECUTIVE OFFICER
» MORE
March 31, 2010
MABCURE CEO ARTICLE FEATURED IN THE APRIL ISSUE OF "DRUG DISCOVERY NEWS"
» MORE
February 1, 2010
MABCURE FEATURED IN GENOMEWEB
» MORE
January 6, 2010
MABCURE LAUNCHES CLINICAL TRIAL TO DIAGNOSE OVARIAN CANCER
» MORE
November 4, 2009
MABCURE SIGNS RESEARCH AGREEMENT WITH BRUGGE, BELGIUM HOSPITAL
» MORE
September 29, 2009
MABCURE PRODUCES MONOCLONAL ANTIBODIES AGAINST COLORECTAL CANCER
» MORE
September 1, 2009
MABCURE CEO ARTICLE FEATURED IN THE SEPTEMBER ISSUE OF GENŽ
» MORE
August 25, 2009
MABCURE FEATURED IN BIOWORLDŽ TODAY
» MORE
August 18, 2009
ARTICLE BY MABCURE CEO -- TUMOUR-SPECIFIC MARKERS: THE HOLY GRAIL OF CANCER DIAGNOSTICSG
» MORE
August 7, 2009
MABCURE APPEARS IN ARTICLE ON "THE USE OF BIOMOLECULES IN DIAGNOSTIC TESTING
» MORE
MabCure, Inc.
MabCure is a biotechnology company whose vision is to change the perception of cancer as a largely incurable disease. MabCure's primary mission is to develop novel diagnostics for the early detection of cancer when the disease is still localized and treatable, and where the chances for cure are greater than 90 percent.
MabCure’s longer term goals are to provide physicians with novel antibodies and drugs that effectively attack only cancer cells while sparing normal tissue and minimize toxic side effects.
[Video] See President & CEO, Dr. Amnon Gonenne, talk about MabCure and its technology.